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Abstract  29 
The global spread of antimicrobial resistance and the increasing number of immune-compromised 30 
patients are major challenges in modern medicine. Targeting bacterial virulence or the human host 31 
immune system to increase host defence are important strategies in the search for novel antimicrobial 32 
drugs. We investigated the inflammatory response of the synthetic short antimicrobial peptide LTX21 33 
in two model systems: a human whole blood ex vivo model and in a murine in vivo peritoneum model 34 
- both reflecting early innate immune response.   35 
In the whole blood model, LTX21 increased secretion of a range of different cytokines, decreased the 36 
level of tumour necrosis factor (TNF), and activated the complement system. In a haemolysis assay, 37 
we found 2.5% haemolysis at a LTX21 concentration of 500 mg/L. 38 
In the murine model, increased influx of white blood cells (WBC) and polymorphonuclear neutrophils 39 
(PMN) in the murine peritoneal cavity was observed after treatment with LTX21. In addition, LTX21 40 
increased monocyte chemoattractant protein-1 (MCP-1). 41 
In conclusion, LTX21 affected the inflammatory response; the increase in cytokine secretion, 42 
complement activation and WBC influx indicates an activated inflammatory response. The present 43 
results indicate impact of LTX21 on host-pathogen interplay. Whether this will also affect the course 44 
of infection has to be investigated. 45 
 46 
 47 








The global spread of antimicrobial resistance and the increasing number of immune-compromised 54 
patients are major challenges in modern medicine (1). The search for novel antimicrobial drugs now 55 
includes agents targeting bacterial virulence or host defence immunity (2). Cationic host defence 56 
peptides (HDPs) are a diverse class of molecules, acting as a first-line defence against microbial 57 
threats (3, 4). Their modes of action are not completely resolved but a proposed central mechanism is 58 
bacterial membrane disruption affecting both dormant and dividing bacteria (5). However, studies 59 
indicate that the lytic effect may be less important under physiologically relevant conditions (6, 7). A 60 
potential important function of HDP s are immune-modulating effects enhancing protective immunity 61 
and suppressing inflammation (8, 9). During infection, HDPs may reduce levels of pro-inflammatory 62 
cytokines, modulate the expression of chemokines, enhance recruitment and activation of immune 63 
cells and stimulate angiogenesis and wound healing (3, 6, 10). Hence, they have potential as new 64 
antimicrobial, immune-modulating drugs. Strategies to improve HDP’s function and reduce toxicity 65 
include design, modification and synthesis of peptide sequences with improved pharmacokinetic, 66 
antimicrobial or immune modulating properties (3, 11).  67 
We have previously reported that short synthetic antimicrobial peptides (SAMPs) have a 68 
superior in vitro killing of biofilm-embedded Coagulase negative staphylococci (CoNS) compared to 69 
Vancomycin (12). In a follow-up study, we compared the efficacy of Vancomycin versus a SAMP 70 
(LTX21) in a murine peritonitis CoNS-infection model (13). Eradication of CoNS biofilms was not 71 
achieved, but LTX21 therapy reduced the bacterial load similar to Vancomycin. Moreover, we found 72 
modulation of the immune response among mice treated with LTX21, which was not seen in mice 73 
treated with Vancomycin or placebo (13).  74 
The aim of the present study was to investigate potential immune modulating properties of LTX21 on 75 
the innate immune response in two different model systems; a human whole blood ex vivo model 76 
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reflecting an early innate immune response and a murine peritoneal in vivo model, reflecting both an 77 
early and a late innate immune response.  78 
 79 
Materials and methods 80 
 81 
LTX21 82 
LTX21 (Lytix Biopharma, Norway) is a tetra-peptide (arginine-tri-tert-butyl-tryptophan-arginine), 83 
derived from bovine lactoferricin (5). The two arginine moieties provide cationic properties and the 84 
modified tryptophan provides the lipophilic bulk. LTX21 powder was dissolved in NaCl to final 85 
concentrations between 25 mg/L and 1000 mg/L for the different ex vivo and in vivo experiments.  86 
 87 
Human whole blood ex vivo model 88 
This model has been described earlier (14, 15). Briefly, for each experiment, approximately 25 ml 89 
fresh blood from each of the six healthy donors was used. The Regional Committee for Medical 90 
Research Ethics approved the collection of blood from healthy adults (2011/2020/REK nord). 91 
Informed written consent was obtained from the blood donors before the experiments were started. 92 
The anticoagulant lepirudin (Refludan®, Hoechst, Sanofi-Aventis, Frankfurt am Main, Germany) was 93 
added to the collected blood at a concentration of 50 µg/ml and the experiments were performed in six 94 
parallels, with different donors each time. The effect of LTX21 on innate immunity components in 95 
human whole blood was compared to placebo (0.9% NaCl) and assessed at two different 96 
concentrations, 50 mg/L and 500 mg/L which is 10 and 100 times the minimal inhibitory 97 
concentrations (MIC) of LTX21 against Staphylococcus epidermidis (13) . All experiments were 98 
started within 30 min after blood collection and LTX21 was added immediately before incubation. 99 
Samples were added to silicone tubing (MediPlast, Malmø, Sweden,) which was circularized and 100 
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incubated rotating at 37 °C for 30 or 180 min. After incubation the samples were centrifuged and 101 
plasma was collected and stored at -80°C until further analyses. We performed two different readouts 102 
of these experiments. First, we determined complement activation in plasma after 30 min incubation. 103 
Second, we determined cytokine concentrations in plasma after 180 min incubation.  104 
  105 
Murine peritoneum in vivo model 106 
Forty-six female BALB/c mice (Taconic M&B A/S Ry, Ejby, Denmark), aged 12 weeks were used. 107 
There were eight mice per cage and all mice had access to water and food ad libitum. The animal 108 
studies were performed in accordance to the ARRIVE guidelines and the European Convention and 109 
Directive for the Protection of Vertebrate Animals Used for Experimental and Other Scientific 110 
Purposes and the Danish law on animal experimentation. The animal experiments were approved by 111 
the National Animal Ethics Committee, Denmark.  112 
All animals received intraperitoneal injections (400 µl) of LTX21 500 mg/L or placebo (0.9% 113 
NaCl) every 24 hours for up to three days. The LTX21 dosage was 10 mg/kg, based on previous 114 
toxicology studies, a pilot treatment study and in vitro MIC studies (data not shown) and a previous in 115 
vivo study comparing the effects of LTX21 versus vancomycin (13). In order to study early 116 
immunomodulatory effects of LTX21, mice were sacrificed three hours after the first intraperitoneal 117 
administration of LTX21 (n=10) or placebo (n=10) on day one. In order to study late 118 
immunomodulatory effects mice were sacrificed three hours after the third intraperitoneal 119 
administration of LTX21 (n=10) or placebo (n=10) on day three. One group of mice without any 120 
interventions (n=6) were included as normal controls and sacrificed on day one.  121 
 Blood sampling and peritoneal lavage were performed after the mice were deeply sedated with 122 
a subcutaneous injection of 0.1 ml pentobarbital 200 mg/ml (KVL, Copenhagen, Denmark). Blood 123 
was drawn by cardiac puncture and transferred to tubes with added heparin (LEO Pharma A/S, 124 
Ballerup, Denmark) for further analyses. Peritoneal lavage was performed by injecting 3 ml 125 
phosphate-buffered saline (PBS) into the peritoneal cavity, followed by gentle massage of the 126 
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abdomen before withdrawing peritoneal lavage fluid (PLF). Mice were euthanized by removal of the 127 
heart whilst in deep sedation. By the end of all experiments 100 µl of PLF was spread on blood agar 128 
plates to check bacterial growth due to possible perforation of the intestine during the intraperitoneal 129 
injections, which could influence inflammatory markers.  130 
 131 
Enzyme immune assays for cytokines. 132 
From the human whole blood assay, plasma from samples incubated for 180 minutes were analysed to 133 
quantify the level of 27 different cytokines (Table 1) using Bioplex cytokine assays (Bio-Rad, 134 
Hercules, CA, USA) according to the manufacturer’s instructions. From the murine in vivo model, five 135 
cytokines (TNF-α, IL-1β, MIP-2 MCP-1 and GM-CSF) were quantified both in plasma and PLF by 136 
using Luminex® Assays (R&D systems, Inc., Minneapolis, MN, USA), according to the 137 
manufacturer’s description. The selection of cytokines quantified in the murine in vivo model, was 138 
based on the findings from the human whole blood model and previously published work of a similar 139 




Enzyme immune assays for complement activation products 144 
In the human whole blood ex vivo model central complement activation products C5a, C4bc, C3bBbP, 145 
C3bc and TCC were quantified by enzyme-linked immunosorbent assay as previously described, in 146 
plasma from samples incubated for 30 minutes (16, 17). 147 
 148 
Cellular response and flow cytometry 149 
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We measured the total white blood cell (WBC) count and polymorphonuclear neutrophils (PMNs) in 150 
murine blood and PLF in response to LTX21 or NaCl, as described previously (13) Briefly, the total 151 
WBC count was determined by staining with allophycocyanin-conjugated monoclonal rat anti-mouse 152 
CD45 antibody (Becton Dickinson, Franklin Lakes, NJ, USA). Fractions of PMNs were estimated by 153 
staining with allophycocyanin-conjugated rat anti-Ly-6G antibody (Becton Dickinson, Franklin Lakes, 154 
NJ, USA), fluorescein isothiocyanate-conjugated rat anti-mouse F4/80 antibody (BioLegend, San 155 
Diego, CA, USA), and peridinin chlorophyll protein complex-conjugated monoclonal rat anti-mouse 156 
CD45 antibody (Becton Dickinson, Franklin Lakes, NJ, USA). The samples were fixed with 10% 157 
FACS lysing solution (Becton Dickinson, Franklin Lakes, NJ, USA) and analysed on a FACSCanto 158 
(Beckton Dickinson, Franklin Lakes, NJ, USA) equipped with a 15-mW argon-ion laser tuned at 488 159 
nm and a red diode laser at 635 nm for excitation. Light scatter and logarithmically amplified 160 
fluorescence parameters for >10000 events were recorded in list mode after gating on forward light 161 
scatter and fluorescence for CD45 staining to excluded debris, cell aggregates and bacteria. The 162 
instrument was calibrated with CST beads (Becton Dickinson, Franklin Lakes, NJ, USA). 163 
 164 
Haemolytic activity  165 
As an indicator of cytotoxicity, the haemolytic activity of LTX21 was determined in human plasma 166 
and NaCl, as previously described (17). Briefly, human erythrocytes from fresh whole blood were 167 
prepared by centrifugation at 194 x g (Eppendorf, Hamburg, Germany) and washed three times with 168 
preheated NaCl before being diluted to 10% in either physiological NaCl or pooled human plasma. 169 
The erythrocytes were incubated for 1 hour at 37°C with LTX21 at concentrations ranging from 25 to 170 
1000 mg/L. The samples were centrifuged at 344 x g (Eppendorf, Hamburg, Germany) for 5 min 171 
before absorbance of the supernatant was measured at 405 nm in a microplate reader (Versamax®, 172 
Molecular Devices, San Jose, CA, USA). Positive controls were human erythrocytes treated with 10% 173 
Triton (Teknova, Hollister, CA, USA) and the negative control was physiological NaCl. The 174 
experiments were repeated three times with different blood donors in two parallel experiments. A 175 
haemolysis ≤ 2.5% does not seem to cause a clinically relevant influence on release of potassium and 176 
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other intracellular substances (18), whereas higher values will increasingly become clinically 177 
significant and potentially dangerous for the host (19). 178 
 179 
Statistical analyses  180 
Data were analyzed using IBM-SPSS version 25 (IBM, Armonk NY, USA) statistical software. The 181 
non-parametric Mann-Whitney U-test was used to compare two groups. We used a Bonferroni 182 
correction when testing the cytokines and complement at two different LTX21 concentrations, and for 183 
these analyses a p value < 0.025 was considered statistically significant. For all other analyses a p 184 
value < 0.05 was considered statistically significant. 185 
 186 
Results  187 
Clinical appearance of the mice 188 
All mice were in good clinical condition before each treatment. The group treated with NaCl remained 189 
clinically unchanged after treatment. In mice treated with LTX21, a change in behaviour and 190 
appearance was noticed during the first 20 min after administration, the mice became less active, had 191 
ruffled fur and huddled closely together. Within one hour post administration, their activity level was 192 
restored and their clinical appearance was the same as the placebo treated and control mice. 193 
 194 
Bacterial growth in murine peritoneal lavage fluid (PLF) 195 
PLF from one of the placebo treated mice had 1,1x 10 3 CFU/ml indicating a possible bacterial 196 
contamination from intestinal perforation. Data obtained from this mouse was excluded from all 197 
analyses. In five other placebo mice 10 CFU/ml was observed, this was not considered significant 198 
contamination or intestinal perforation that would affect the results of the study.  This is confirmed by 199 
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the significant increase found in several inflammatory markers for the LTX21 treated mice compared 200 
to placebo mice, described below.  201 
 202 
Cellular responses in murine peritoneal lavage fluid (PLF) 203 
We found significantly higher total levels of WBCs in PLF among mice treated with LTX21 compared 204 
to placebo, both on day one (p=0.023) and day three (p=0.002) (Figure 1a). A significant increase in 205 
the WBCs was observed from day one to day three (p=0.019) in the LTX21 group. Similarly, there 206 
were significantly higher levels of PMNs in PLF among mice treated with LTX21 compared to 207 
placebo, both on day one (p<0.001) and day three (p<0.001) (Figure 1b).  208 
 209 
Cellular responses in murine blood 210 
There were higher levels of PMNs in mice treated with LTX21 compared to placebo both on day one 211 
(p=0.01) and on day three (p<0.001) (Figure 2b). No significant differences in WBCs were found 212 
between the LTX21 and placebo, neither on day one nor three (Figure 2a).  Both WBC (p= 0.015) and 213 
PMN (p= 0,009) levels decreased in the placebo group from day one to three, while only a significant 214 
fall in WBC level was observed in the LTX21 group (Figure 2b). 215 
 216 
Cytokine secretion in murine plasma and PLF 217 
We detected increased levels of the monocyte chemoattractant protein-1 (MCP-1) in both plasma (p 218 
<0.001) and PLF (p <0.001) among mice treated with LTX21 compared to placebo on day one (Figure 219 
3a and b). On day three we only found significantly higher levels of MCP-1 in the PLF (p = 0.011), 220 
but not in plasma, among mice treated with LTX21 (Figure 3a and b). There was a significant decrease 221 
in MCP-1 levels from day one to three in both PLF (p= <0.001) and plasma (p <0.001). The other 222 
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cytokines measured in plasma from mice treated with LTX21 or placebo showed no significant 223 
biological relevant differences.  224 
 225 
Cytokine secretion in human plasma  226 
A significant increase of cytokine secretion in plasma from blood exposed to LTX21was observed 227 
compared to blood exposed to NaCl. In Table 1 we present cytokines showing significant change 228 
compared to the control after LTX21 exposure. LTX21 induced cytokine secretion in a dose-229 
dependent manner for several cytokines. In contrast, we observed a significant decrease in TNF-α 230 
secretion in response to LTX21.  231 
 232 
Complement activation in human whole blood  233 
In the ex vivo human whole blood model, we observed significant complement activation as measured 234 
for C5a and TCC in response to LTX21 at a concentration of 500 mg/L (Table 2). The lower LTX21 235 
concentration (50 mg/L) did not significantly activate the complement system.  236 
 237 
Haemolytic effects of LTX21 in plasma 238 
LTX21 induced haemolysis at concentrations ≥100 mg/L, while concentrations ≥500 mg/L resulted in 239 
very high haemolysis (Figure 4) when erythrocytes where diluted in NaCl. Haemolysis was markedly 240 
reduced when erythrocytes where diluted in physiological plasma solution. Under this latter condition 241 





Our results show that the response to LTX21-in the human whole blood model was dominated by 245 
induced cytokine secretion and an activation of the complement system. In the murine peritoneal 246 
model, we found significant increases in WBC counts, particularly PMNs as a response to LTX21. 247 
 The immune response during an infection is largely mediated by cytokines e.g. by attracting 248 
WBCs to the site of infection and thus augmenting the immune response. We observed a significant 249 
increase in several pro- and anti-inflammatory cytokines as a response to LTX21 in the ex vivo human 250 
whole blood model. However, not all cytokines increased in a dose-dependent manner, and some, 251 
albeit statistically significant, increased only modestly with uncertain biological significance.  252 
A clear dose-dependent increase was observed for the chemokine MCP-1, eotaxin and VEGF 253 
which all play a role in angiogenesis (20). The only cytokine displaying reduced levels, was TNF, 254 
which is an important pro-inflammatory cytokine in the acute phase response of innate immunity (21). 255 
Increase in chemokines and reduced levels of TNF secretion has previously been shown in response to 256 
synthetic cationic peptides (22, 23). In the murine model, MCP-1 was increased in response to LTX21, 257 
a response also described previously for other synthetic HDPs (22). MCP-1 is primarily secreted by 258 
monocytes, macrophages and dendritic cells and recruits more of these cells to the site of 259 
inflammation (24, 25). Resident peritoneal macrophages are known to be an important source of 260 
chemokines for leukocyte recruitment during peritoneal infections and were probably one of the cell 261 
types that increased MCP-1 production in response to LTX21 (26-28). A significant increase in 262 
activation of the terminal complement pathway was observed for LTX21 in the ex vivo whole blood 263 
model. This supports the theory that both natural HDPs and synthetic peptides may activate the host 264 
immune defence. However, they seem to cause a more modest inflammatory response in contrast to 265 
the strong and often inappropriate pro-inflammatory response observed after stimulation with Gram 266 
negative cell wall components (lipopolysaccharides) (29). Our findings are also in line with recent data 267 
reporting complement activation in response to synthetic cationic peptides (30).  268 
In the murine model increased influx of WBCs, and in particular PMNs, to the peritoneal cavity was 269 
found, indicating that LTX21 induces a biologically significant inflammatory response. Other studies 270 
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have shown that HDPs induce chemotaxis of WBC/PMNs through stimulation of chemokine secretion 271 
in addition to suppression of potentially harmful inflammation (22, 23, 31, 32). We could not detect 272 
any increased levels of cytokines attracting PMNs. Other studies have shown that some HDPs are 273 
chemotactic themselves and induce WBC/PMN influx without the production of cytokines (33). The 274 
observed influx of immune cells in response to LTX21 and other lactoferricin-derivates has to our 275 
knowledge not previously been studied, and calls for further investigation of the mechanisms. We did 276 
not measure complement products in the murine model. We can therefore not rule out that 277 
complement-mediated recruitment of PMNs could be an explanation for our finding.  However, a pilot 278 
study (data not published) indicate that LTX21 does not significantly activate complement in the 279 
animal model setup used in this study. Another limitation with our study is that we did not check 280 
specifically for obligate anaerobes when plating the peritoneal fluid, since anaerobe bacteria make up a 281 
significant proportion of the gut microbiome they could theoretically explain some of the 282 
inflammatory response observed in the placebo group. 283 
 Mammalian cytotoxicity differs between different HDPs. We tested the cytotoxicity of LTX21 284 
in a haemolysis assay with human erythrocytes in human plasma. The amphipathic structure of 285 
LTX21, with its hydrophobic and cationic residue is an important hallmark of antimicrobial peptides, 286 
mimicking the mammalian membranes. There is a well-known correlation between increased 287 
hydrophobicity and increased lysis of erythrocytes (34, 35). In our study, haemolysis was low even at 288 
the highest LTX21 concentration (1000 mg/L) when we used a physiologically relevant media. This 289 
reflects how complex biological environments and possible peptide binding to plasma proteins may 290 
reduce the potential of HDP’s toxicity to mammalian cells compared to in vitro findings using assays 291 
with NaCl (36, 37).  292 
 We have used the synthetic peptide LTX21, structurally  closely related to LTX109 293 
(Lytixar™), a drug already evaluated in human clinical trials (38). LTX109 is a promising drug for 294 
nasal decontamination of methicillin-resistant Staphylococcus aureus and treatment of Gram-positive 295 
skin infections (38). The antimicrobial and antifungal effects of LTX109 have been extensively 296 
investigated (12, 39, 40). However, this is the first study where the innate immune response to the 297 
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closely related peptide LTX21 is examined both under ex vivo and in vivo conditions. The immune-298 
modulatory effects of synthetic HDPs have not been explored to the same extent as their antimicrobial 299 
properties. Prophylactic treatment with protease-labile L-amino acid peptides may reduce both local 300 
and systemic infections in mice acting as an immune defence regulator (23). Our observations are in 301 
agreement with these findings, indicating that further studies should be repeated in an in vivo model, 302 
assessing both the early and the late inflammatory response in addition to further mechanistic studies 303 
assessing the potential of LTX21 in regulating proinflammatory cytokines, and alleviating 304 




LTX21 induced cytokine secretion and activated the complement system in the human whole blood 307 
model and induced influx of WBC and PMNs in a murine peritoneal model. The most pronounced 308 
effect; increase in chemokine secretion and PMN influx, points towards similar functions as those 309 
previously described for other HDPs. The PMN influx to the treatment site in the in vivo model may 310 
enhance the bacterial killing. LTX21 induced innate immune responses, which may augment the 311 
inflammatory response during an infection. Additionally, the reduced TNF secretion may even prevent 312 
some of the tissue damage mediated by this cytokine during severe immune responses. Further in vivo 313 
experiments are necessary to study how LTX21 may affect the course of an infection alone or in 314 
combination with traditional antibiotics.   315 
 316 
Abbreviations 317 
HDP Host defence peptides 318 
PMN Polymorphonuclear neutrophils 319 
CoNS Coagulase negative staphylococci 320 
CFU Colony-forming units 321 
FACS Fluorescence-activated cell sorting 322 
ELISA Enzyme-linked immunosorbent assay 323 
WBC White blood cells 324 
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Table 1. LTX21 induced cytokine responses in an ex vivo human whole blood model after 3 h 443 
incubation. Interval data are presented as median (IQR). Concentrations of the cytokines are 444 
given in pg/ml. Of the 27 cytokines studied, this table includes those (n=13) with significant 445 
differences between the groups. 446 
Cytokin 
(pg/ml)  Control
1 LTX21                      50mg/L  
LTX21                   
500mg/L 
P-value2                
Control vs 50mg/L 
P-value2                       
Control vs 500mg/L 
IL2 0 (0-3.25) 6.5 (5-7.25) 12 (12-13) 0.002 0.002 
IL6 3.5 (2.5-4.0) 5.5 (3.75-6) 14 (9.75-14) 0.041 0.002 
IL10 15 (13-17) 23 (21-30) 32 (22-59) 0.009 0.002 
IL13 5 (4.5-7.25) 6.5 (4.75-7.25) 14 (9.75-25) 0.132 0.002 
IL15 0 (0) 0 (0) 7.5 (3-12) 1.0 0.015 
Eotaxin 39 (32-48) 57 (41-72) 92 (75-110) 0.093 0.002 
GMCSF 0 (0) 29 (8.5-36) 85 (62-100) 0.002 0.002 
IP10 301 (225-394) 525 (379-725) 869 (606-1314) 0.026 0.004 
MCP1 7 (6-12) 15.5 (14-24) 40 (30-45) 0.004 0.004 
MCP1α 3 (1.5-4.5) 6.5 (5-8.5) 9.5 (8.75-13) 0.009 0.004 
PDGFBB 906 (710-1026) 2472 (2066-2914) 3189 (2090-3724) 0.002 0.002 
TNF 51 (43-63) 48 (48-53) 29 (24-44) 1.0 0.002 
VEGF 18 (17-25) 41 (30-57) 102 (85-133) 0.009 0.002 
 447 
1Untreated control: human blood and PBS.  448 
2p value is determined by Mann-Whitney U-test. Bonferroni correction was done and a ρ value <0.025 449 










Table 2. Complement activation by LTX21 in an ex vivo human whole blood model after 30 min 458 
incubation. Interval data are presented as median (IQR) 459 
Complement  
activation product Control
1 LTX21 50mg/L 
LTX21       
500 mg/L 
P-value2               
Control vs 50 mg/L 
P-value2                 
Control vs 500 mg/L 
C4bc (CAU/ml) 31 (16-49) 28 (16-48) 59 (32-180) 0.937 0.093 
C3bBbP (CAU/ml) 585 (464-879) 509 (398-650) 548 (320-994) 0.485 0.937 
C3bc (CAU/ml) 55 (41-62) 46 (36-61) 81 (55-121) 0.589 0.132 
C5a (ng/ml) 46 (42-57) 45 (29-56) 191 (153-249) 0.699 0.002 
TCC (CAU/ml) 25 (16-35) 24 (16-37) 52 (42-110) 1 0.004 
 460 
1 Human blood and PBS 461 
2p-value determined by Mann-Whitney U-test with a Bonferroni correction test; a p-value <0.025 was 462 



















Fig. 1 a: Levels of white blood cell count (WBC) in peritoneal lavage fluid (PLF) after treatment with 480 
LTX21 or NaCl.  481 
The number of WBC were estimated in PLF from mice treated with either LTX21 or NaCl once 482 
(sacrificed on day 1) or three times with 24 h intervals (sacrificed on day 3). Controls were six mice 483 
sacrificed on day 1 without any intervention or treatment.   484 
*p < 0.05, **p < 0.01, ***p < 0.001; differences within one day (solid lines) 485 
22 
 
*p < 0.05, **p < 0.01, ***p < 0.001; differences between days (dotted lines). With comparison 486 
between days; comparison of the same substance on two different days. 487 
 488 
Fig. 1 b: Amount of polymorphonuclear neutrophils (PMNs) in peritoneal lavage fluid (PLF) after 489 
treatment with LTX21 or NaCl.  490 
The amount of PMNs were estimated in PLF from mice treated with either LTX21 or NaCl once 491 
(sacrificed on day 1) or three times with 24 h intervals (sacrificed on day 3). Controls were six mice 492 
sacrificed on day 1 without any intervention or treatment.   493 





Fig. 2 a: Levels of white blood cell count (WBC) in murine blood after treatment with LTX21 or 497 
NaCl. The number of WBC were estimated in blood from mice treated with either LTX21 or NaCl 498 
mice (sacrificed on day 1) or three times with 24 h intervals (sacrificed on day 3). Controls were six 499 
mice sacrificed on day 1 without any intervention or treatment.   500 
*p < 0.05, **p < 0.01, ***p < 0.001; differences between days (dotted lines). With comparison 501 





Fig. 2 b: Amount of polymorphonuclear neutrophils (PMNs) in murine blood after treatment with 505 
LTX21 or NaCl. The amount of PMNs were estimated in blood from mice treated with either LTX21 506 
or NaCl mice (sacrificed on day 1) or three times with 24 h intervals (sacrificed on day 3). Controls 507 
were six mice sacrificed on day 1 without any intervention or treatment.  508 
*p < 0.05, **p < 0.01, ***p < 0.001; differences within one day (solid lines) 509 
*p < 0.05, **p < 0.01, ***p < 0.001; differences between days (dotted lines). With comparison 510 





Fig. 3a: Level of Monocyte chemoattractant protein-1 (MCP-1) in peritoneal lavage fluid (PLF) after 514 
treatment with LTX21 or NaCl. 515 
The level of MCP-1 was estimated in PLF from mice treated with either LTX21 or NaCl once 516 
(sacrificed on day 1) or three times with 24h intervals (sacrificed on day 3). Controls were six mice 517 
sacrificed on day 1 without any intervention or treatment. 518 
*p < 0.05, **p < 0.01, ***p < 0.001; differences within one day (solid lines) 519 
*p < 0.05, **p < 0.01, ***p < 0.001; differences between days (dotted lines). With comparison 520 




Fig. 3b: Level of Monocyte chemoattractant protein-1 (MCP-1) in plasma after treatment with LTX21 523 
or NaCl. 524 
The level of MCP-1 was estimated in blood from mice treated with either LTX21 or NaCl once 525 
(sacrificed on day 1) or three times with 24h intervals (sacrificed on day 3). Controls were six mice 526 
sacrificed on day 1 without any intervention or treatment. 527 
*p < 0.05, **p < 0.01, ***p < 0.001; differences within one day (solid lines) 528 
*p < 0.05, **p < 0.01, ***p < 0.001; differences between days (dotted lines). With comparison 529 





Fig. 4: Haemolytic activity of LTX21 on human erythrocytes. Haemolytic activity of LTX21 was 533 
determined in NaCl and plasma. Each line represents the average of two parallel samples from 3 534 
donors. Error bars display the standard error of mean. 535 
 536 
